BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement

Published · Updated Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

Key Takeaways

  • The single reportable segment accounts for 100% of the $353.17 M of revenue.
  • Net product revenue was $253.35 M, 72% of the total, with license at $79.31 M.
  • License and services revenue rose 9.5 times in a year, from $8.31 M to $79.31 M.
  • Royalty revenue rose from $4.28 M to $20.51 M on Beyonttra sales in the EU and Japan.

The Unvarnished Truth

One segment, three revenue lines, and product sales carry 72%

The business view is one segment: the Reportable Segment accounts for 100% of the $353.17 M of revenue. Inside it, net product revenue is $253.35 M, license and services revenue $79.31 M, and royalty revenue $20.51 M. Product sales carry 72% of the total, and the rest is a mix of milestones and royalties from partners. The company says it runs one business, so this view splits one business into three lines, not three businesses. That is the filing's own framing, not ours.

The quarter's growth came from the smaller lines. License and services revenue rose from $8.31 M to $79.31 M, or 9.5 times its level a year earlier, while net product revenue grew 134%. The filing ties that license jump to the $75.0 M milestone, so product sales are the steady part and license revenue is the lumpy part. Nine months tell the same story, with license revenue down 29% from a year earlier while product sales climbed.

What it means: one name, three businesses. Royalty revenue rose from $4.28 M to $20.51 M on Beyonttra sales in the EU and Japan, and the filing expects more from partners such as Bayer and Alexion. Products that sell, licenses that pay out once, and royalties that depend on partners' sales do not behave alike. Mixing them into one segment hides which line is carrying the company. Will royalty revenue keep rising as partners sell more, or will milestones keep the top line lumpy?

2026-07-01 to 2026-09-30

Revenue by Business Segment by Product and Service

Swipe to see the full flow
BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income StatementIncome statement for 2026-07-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETReportable Segment - Net product revenueReportable Segment - License and services revenueReportable Segment - Royalty revenueTotal revenues, netGross profit (calculated)Total cost of revenuesLoss from operationsOperating expenses (calculated)Selling, general and administrativeResearch and developmentLoss before income taxesTotal other expense, netNet lossProvision for (benefit from) income taxesGross profit (calculated)Gross profit(calculated)$332.72 MLoss before income taxesLoss beforeincome taxes−$59.27 MTotal revenues, netTotal revenues, net$353.17 MLoss from operationsLoss from operations−$11.64 MNet lossNet loss−$60.50 MOperating expenses (calculated)Operating expenses(calculated)$344.36 MReportable Segment - Net product revenueReportable Segment -Net product revenue$253.35 MProvision for (benefit from) income taxesProvision for (benefitfrom) income taxes$1.23 MSelling, general and administrativeSelling, general and administrative$200.85 MReportable Segment - License and services revenueReportable Segment - Licenseand services revenue$79.31 MTotal cost of revenuesTotal cost of revenues$20.45 MReportable Segment - Royalty revenueReportable Segment - Royalty revenue$20.51 MResearch and developmentResearch and development$143.51 MTotal other expense, netTotal otherexpense, net−$47.63 M
Chart details

BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 P&L / Income Statement

Income statement for 2026-07-01 through 2026-09-30. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues, net
353,171,000 US dollars
Total cost of revenues
20,450,000 US dollars
Gross profit (calculated)
332,721,000 US dollars
Operating expenses (calculated)
344,360,000 US dollars
Loss from operations
negative 11,639,000 US dollars
Total other expense, net
negative 47,628,000 US dollars
Loss before income taxes
negative 59,267,000 US dollars
Provision for (benefit from) income taxes
1,229,000 US dollars
Net loss
negative 60,496,000 US dollars
Reportable Segment - License and services revenue
79,314,000 US dollars
Reportable Segment - Net product revenue
253,346,000 US dollars
Reportable Segment - Royalty revenue
20,511,000 US dollars
Restructuring, impairment, and related charges
0 US dollars
Research and development
143,506,000 US dollars
Selling, general and administrative
200,854,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Of which attributable to BridgeBio Pharma, Inc.: −$56.71 M; to noncontrolling interests: −$3.79 M.
BridgeBio Pharma, Inc. (BBIO) FY2026 Q3 Revenue by Business Segment by Product and Service Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Intelligent Insights for Investors

What is inside the biggest piece of BridgeBio's sales?

The reportable segment is the whole picture: its listed products brought in 100% of sales this quarter, and product revenue made up 72% of them.

Which parts of BridgeBio's sales by business drove the change over the past year?

Net product revenue did most of the work: it grew 134% this quarter and accounted for 62% of the increase in revenue.

Intelligent Insights for Suppliers

How much does BridgeBio depend on the biggest piece of its sales by business?

Heavily: product revenue brought in 72% of these sales this quarter, against 22% for license and services revenue, the next largest.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!